Remarkably, combining rapamycin with FASN inhibition promotes DLBCL cell death (Figure 5b,c), therefore indicating that combining inhibition of the mTOR oncogenic pathway and FA metabolism has a broader metabolic impact on DLBCL cells, thereby impacting more strongly of their survival (both OxPhos and glycolytic, ABC and GCB). Here, FASN is linked to diffuse large B-cell lymphoma.